4D Molecular Therapeutics Inc (FDMT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
4D Molecular Therapeutics Inc (4DMT) is a gene therapy company that discovers and develops targeted and proprietary AAV gene therapy vectors and therapeutic products. The company’s pipeline products include 4D-125, 4D-110, 4D-150, 4D-175, 4D-310, 4D-725, and 4D-710. It has developed a technology platform, Therapeutic Vector Evolution, that facilitates the creation of customized gene delivery vehicles (novel AAV vectors) to deliver genes to any tissue or organ in the body. 4DMT develops pipeline products that target areas such as liver, retina, heart, brain, skeletal muscle, and lungs. The company works in partnership with F. Hoffmann-La Roche Ltd to design, develop and commercialize AAV products for use in ophthalmology indications. 4DMT is headquartered in Emeryville, California, the US.4D Molecular Therapeutics Inc Key Recent Developments
- Feb 29, 2024: 4DMT Reports Full Year 2023 Financial Results and Operational Highlights
- Jan 04, 2024: 4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
- Sep 12, 2023: 4DMT Appoints Uneek Mehra as Chief Financial and Business Officer
- Aug 09, 2023: 4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- RegenxBio Inc
- Regeneron Pharmaceuticals Inc
- Takeda Pharmaceutical Co Ltd
- Innostellar Biotherapeutics Co Ltd
- Amicus Therapeutics Inc
- Vertex Pharmaceuticals Inc
- Sanofi Genzyme US
- Protalix BioTherapeutics Inc
- Recode Therapeutics Inc
- Krystal Biotech Inc
- Apellis Pharmaceuticals Inc
- Opthea Ltd
- EyePoint Pharmaceuticals Inc
- Adverum Biotechnologies Inc
- AbbVie Inc
- Arcturus Therapeutics Holdings Inc